| 11β-HSD2 | 11β-hydroxysteroid dehydrogenase type 2 |
| ACEi | angiotensin converting enzyme inhibitor |
| Ang II | angiotensin II |
| ARB | angiotensin receptor blocker |
| ASI | aldosterone synthase inhibitor |
| CKD | chronic kidney disease |
| CYP11β2 | cytochrome P450 11β2, aldosterone synthase |
| eGFR | estimated glomerular filtration rate |
| ENaC | epithelial sodium channels |
| ESKD | end-stage kidney disease |
| Gal-3 | galectin-3 |
| HFrEF | heart failure with reduced ejection fraction |
| MR | mineralocorticoid receptor |
| MRA | mineralocorticoid receptor antagonist |
| NGAL | Neutrophil Gelatinase-Associated Lipocalin |
| NT-proBNP | N-terminal pro B-type natriuretic peptide |
| PAI-1 | plasminogen activator inhibitor-1 |
| RAAS | renin–angiotensin–aldosterone system |
| Rac-1 | Ras-related C3 botulinum toxin substrate 1 |
| RAS | renin–angiotensin system |
| ROS | reactive oxygen species |
| SGLT2 | sodium–glucose transport protein 2 |
| TGF-β | transforming growth factor-beta |
| UACR | urinary albumin-to-creatinine ratio |